Medtronic plc — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Medtronic reported Q1 FY27 revenue of $9.756B (+13.7% organic), beating guidance by ~200bps, with non-GAAP diluted EPS of $1.45 ahead of expectations. The company raised FY27 organic revenue growth guidance by 50bps to 7.25%–7.75% and raised non-GAAP EPS guidance to $5.94–$6.00. Key drivers: Cardiovascular +18.9% (led by Electrophysiology +29.1%), Neuroscience +9.3%, Medical Surgical +10.2%, and Diabetes +14.9% organic. Completed acquisitions of Scientia Vascular and SPR Therapeutics; announced strategic investment in Pi-Cardia and partnership with Cornerstone Robotics. Note: Q1 includes a beneficial 53rd week (estimated ~$570M impact).
Why this rating
Strong beat and raised guidance are positive, but Q1 includes one-time 53-week benefit (~$570M on $9.8B revenue ≈ 5.8%) that inflates organic growth appearance. Excluding extra week, organic growth ~7.9%—close to prior guidance. Portfolio diversification and M&A activity are healthy but incremental. Relative to $120B market cap, earnings beat and guidance lift are modest; event is typical quarterly upside, not transformational.
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.